- Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc’s (NASDAQ:NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.
- The analyst notes that though NBI-827104 lags behind its competitors, the market opportunity will be attractive given the total addressable market estimated at ~$13 billion, with no recently approved drugs in ET.
- The following data readout for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) and Praxis Precision Medicines Inc’s (NASDAQ:PRAX) second Phase 2 trials are expected in 1H of 2024 and 2H of 2022, respectively.
- Commenting on efficacy, given a similar mechanism of action to Jazz’s JZP385 and Praxis’ PRAX-944, Needham looks for a change in TETRAS-ADL of 5-6 points and TETRAS-ADL of 4-5 points.
- TETRAS is designed for the rapid and valid assessment of ET severity.
- On safety, JZP385 and PRAX-944 both had ~20% discontinuations.
- The analyst says that if NBI-827104’s safety profile can replicate its Phase 1 (~10% discontinuation).
- Needham expects a single-digit upside to shares on a successful study.
- Price Action: NBIX shares are up 1.77% at $97.26 during the market session on the last check Monday.
Edward Snowden Says ‘Bitcoin Fixes This’ In Response To NYSE Trading Glitch That Sank Warren Buffett-Led Berkshire Hathaway Shares
Renowned whistleblower and privacy advocate Edward Snowden used the technical glitch that disrupted trading on the New York Stock Exchange to draw attention to the inherent advantages of cryptocurrencies, notably Bitcoin (CRYPTO: BTC).
